regardless of promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant resistance from PBMs. The organizations are frequently erecting obstacles to reimbursement, including high expense restrictions and approval processes that hinder user availability. Market belie